Becker's Healthcare May 17, 2024
Paige Twenter

Amgen’s Imdelltra is the first and only T-cell engager therapy approved for extensive-stage small cell lung cancer, an aggressive, stubborn cancer that spreads through the body.

On May 16, the FDA granted Imdelltra an accelerated approval. In a trial with 99 study participants with symptomatic brain metastases,...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, FDA, Govt Agencies
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article